A randomized, placebo-controlled trial of granulocyte-macrophage colony-stimulating factor and nucleoside analogue therapy in AIDS

Journal of Infectious Diseases

Volumn 182, Issue 5, 2000, Pages 1531-1535

  Brites, Carlos ^a   Gilbert, Mark J ^d   Pedral Sampaio, Diana ^a   Bahia, Fabiana ^a   Pedroso, Celia ^a   Alcantara, Ana Paula ^a   Sasaki, Maria das Gracas ^c   Matos, Junisia ^b   Renjifo, Boris ^e   Essex, Max ^e   Whitmore, James B ^d   Agosti, Jan M ^d   Badaro, Roberto ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b HOSPITAL SÃO RAFAEL   (Brazil)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^d AMGEN INC   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; NUCLEOSIDE ANALOG; PLACEBO; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; FEVER; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; ZIDOVUDINE;

EID: 0033787449     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315901     Document Type: Article

References (17)

1. Transmission of multidrug-resistant human immunodeficiency virus: The wake-up call
2. Individual cell analysis of the cytokine repertoire in human immunodeficiency virus-1-infected monocytes/macrophages by a combination of immunocytochemistry and in situ hybridization
3. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on HIV-related leukopenia: A randomized, controlled clinical study
4. A pilot study in the use of GM-CSF in human immunodeficiency virus infected individuals
5. Replication of human immunodeficiency virus in monocytes: Granulocyte-macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine
6. Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages
7. Chemokine receptor regulation and HIV type 1 tropism in monocyte-macrophages
8. GM-CSF or CD40L suppresses chemokine receptor expression and HIV-1 entry in human monocytes and macrophages
9. Suppression of HIV replication in human monocyte-derived macrophages induced by granulocyte-macrophage colony-stimulating factor
10. Safety and anti-HIV effect of GM-CSF in patients on highly active antiretroviral therapy
11. Pharmacokinetics and pharmacodynamics of granulocyte-macrophage colony-stimulating factor and zidovudine in patients with AIDS and severe AIDS-related complex
12. Pilot study of low dose zidovudine in human immunodeficiency virus infection
13. Randomized controlled trial of a reduced dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group
14. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group
15. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team
16. Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-Week follow-up
17. Report of the NIH Panel to Define Principles of Therapy of HIV Infection